OMDA · Omada Health, Inc. · Stock research

Current Thesis

Omada is the scaled public pure-play on the question the GLP-1 boom forces every employer and health plan to answer: what happens to a member after the drug — muscle loss, adherence, weight regain on discontinuation? Omada sells the behavior-change wrap-around, and the March quarter showed the model inflecting. Q1 2026 (reported 2026-05-07) revenue rose 42% YoY to $78.0M, adjusted EBITDA turned positive at ~$1M (from –$4M a year earlier), and management lifted FY2026 guidance to $322–330M from $312–322M. The tape has repriced that: from roughly $15 in early May to a $23.44 close on 2026-07-14 and $23.70 by 2026-07-17, about +55%, into a $30 analyst-target cluster (BTIG Buy/$30 on 2026-07-17; Morgan Stanley Overweight/$30 on 2026-06-22; Goldman Buy/$26). The accelerating leg is a digital-chronic-care re-rating where GLP-1 adoption reads as TAM expansion rather than obsolescence. The near-term gate is the Q2 print, estimated early August.

Bullish and bearish views on Omada Health, Inc.

The model's bull view on Omada Health, Inc. (OMDA), in brief: Beat-and-raise already printed. Q1 2026 (2026-05-07): revenue $78.0M, +42% YoY; services $69.6M, hardware $8.5M; gross margin 62.4%; net loss narrowed to $3.0M; adjusted EBITDA ~$1M vs –$4M in Q1 2025. FY2026 guide raised to $322–330M revenue and $14–20M adjusted EBITDA.… The bear view: The existential debate is unresolved. The standing short thesis (e.g., Seeking Alpha, "users may feel they can do without") holds that once a GLP-1 works, coaching is the first line employers cut in a budget squeeze. Omada's persistence data argues against it, but that fear is… Both cases follow in full.

Bull Case

• Beat-and-raise already printed. Q1 2026 (2026-05-07): revenue $78.0M, +42% YoY; services $69.6M, hardware $8.5M; gross margin 62.4%; net loss narrowed to $3.0M; adjusted EBITDA ~$1M vs –$4M in Q1 2025. FY2026 guide raised to $322–330M revenue and $14–20M adjusted EBITDA.
• Membership compounding fast. 1.025M members at Q1-end, +51% YoY, up from 886,000 at YE2025 (itself +55% YoY). GLP-1 members surpassed 150,000 vs >50,000 at YE2024.
• The data point that rebuts the bear. A 12-month real-world study of 965 GLP-1 companion members showed 18.4% weight loss, 67% medication persistence, and only 0.8% average regain one year after discontinuation versus the 11–12% regain seen in drug-only trials — the retention evidence enterprise buyers need to keep funding the layer.
• Guidance carries free option value. The $322–330M FY guide embeds no material contribution from GLP-1 prescribing, Flex Care, or the new cholesterol program; any ramp is upside to the number the Street is modeling.
• Analyst narrative institutionalizing into the print. A tight cluster of bullish actions: BTIG initiation Buy/$30 (2026-07-17), Morgan Stanley reiterated Overweight/$30 (2026-06-22), Goldman raised to $26 from $23, Citizens raised on the growth outlook. Consensus stands at 10 buys, 0 sells, avg PT ~$24.

Bear Case

• The existential debate is unresolved. The standing short thesis (e.g., Seeking Alpha, "users may feel they can do without") holds that once a GLP-1 works, coaching is the first line employers cut in a budget squeeze. Omada's persistence data argues against it, but that fear is why the stock round-tripped from a $25.87 high (Oct 2025) to ~$15 by May.
• Barely profitable on a premium re-rating. Adjusted EBITDA of ~$1M on $78M quarterly revenue is thin, and hardware at ~11% of mix drags blended margin below a pure-SaaS comp. The +55% move has already discounted much of the beat-and-raise ahead of the next proof point.
• Enterprise concentration and long cycles. Revenue rides employer and health-plan contracts with multi-quarter sales cycles; a single large-account loss or a slower 2027 selling season shows up quickly against the 40%+ growth bar the market now prices.
• Stretched into prior-high supply before a binary. At $23.70 the stock sits ~8% under the $25.87 all-time high and enters an estimated early-August print already extended off the May base — the setup where an in-line quarter can still sell off.

Setup & Price Structure

• Trend is up and accelerating: roughly $15 in early May to a $23.44 close (2026-07-14) and $23.70 (2026-07-17), about +55% off the base.
• Overhead pivot is the October-2025 high at $25.87; a decisive weekly close through it opens the $30 zone marked by the BTIG and Morgan Stanley targets, with Goldman's $26 as the waypoint.
• Support ladders down to the $19 IPO price (priced 2026-06-05, opened 2025-06-06) — the shelf the rising base is built on. The June-2025 lockup cleared long ago, so supply from that overhang is behind the tape rather than ahead of it.
• Near term the advance is extended into resistance right before earnings; the clean continuation is a breakout-and-hold above $26, while a stall here that loses the $19–20 base flips the read.

Catalyst Calendar (next 30 days)

• 2026-09-10 — Investor Day (outside 30d). Flagged for the calendar: the venue for GLP-1 prescribing, Flex Care, and cholesterol-program ramp disclosure that current guidance excludes.

Elapsed catalysts

• ~2026-08-06 (est.) — Q2 2026 earnings. Not yet officially dated; Q1 landed 2026-05-07, ~37 days after quarter-end, so a quarter ending 2026-06-30 points to early-to-mid August. The binary set: member growth holding ≥40% YoY, GLP-1 persistence trend, and whether the FY guide gets raised again. (passed 3d ago)
• Ongoing — analyst target clustering. Further initiations or raises toward the $30 high-end (following BTIG on 2026-07-17) would confirm the narrative is being institutionalized before the print; watch for the tape to reach $30 with no fresh upgrades as the saturation signal. (passed 23d ago)

What Would Change Our Mind

• A weekly close below $19 loses the IPO-price shelf and the rising base off the May lows — the signal the accelerating leg has failed rather than paused.
• A Q2 print (est. early August) that shows member growth decelerating through ~40% YoY, a GLP-1 persistence figure rolling over from the 67% / 18.4% marks, or any FY-guidance walk-back — each validates the "coaching is optional" frame.
• Theme rotation: the GLP-1-aftercare / digital-chronic-care trade flipping from an under-owned setup to a crowded one — mainstream coverage, targets bunching at $30 without new upgrades, stock already at $30 — is the saturation tell to stand aside for a cleaner re-entry.

Correlation Notes

• Moves with the GLP-1 complex as a second-order beneficiary: obesity-drug demand (Lilly, Novo) sets the member-funnel backdrop, but Omada's P&L is decoupled from which drug wins the script share.
• Peer read-across to virtual-care and digital-health names, especially Hinge Health — the Morgan Stanley comp, which flagged Omada as more profitable at comparable revenue. A Hinge or Teladoc-style stumble would pressure the group multiple regardless of Omada's own numbers.
• Managed-care and employer-benefits sentiment (UNH and the large payers) sets the enterprise-budget tone; a benefits-cost scare that pushes employers to trim point solutions is the macro channel that reaches Omada indirectly.